These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 2068476

  • 1. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A, Steru D, Rosset MA, Carbon C.
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
    LeFrock JL, Smith BR, Chandrasekar P, Rolston KV, Molavi A, Kannangara W.
    Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E, Bosch-Perez A.
    Chemotherapy; 1989 Feb; 35 Suppl 1():1-7. PubMed ID: 2659288
    [Abstract] [Full Text] [Related]

  • 8. Aztreonam therapy for serious gram-negative bacillary infections.
    Cone LA, Woodard DR.
    Rev Infect Dis; 1985 Feb; 7 Suppl 4():S794-802. PubMed ID: 3909339
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE, Neu HC.
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK.
    Rev Infect Dis; 1985 Feb; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [Abstract] [Full Text] [Related]

  • 12. The clinical use of aztreonam.
    Schönwald S, Schoss-Vidensek Z, Car V, Krznar B.
    Chemotherapy; 1989 Feb; 35 Suppl 1():45-8. PubMed ID: 2731450
    [Abstract] [Full Text] [Related]

  • 13. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD, Jehl F, Froehly S, Dupeyron JP, Monteil H, Rosset MA.
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [Abstract] [Full Text] [Related]

  • 14. Aztreonam.
    Childs SJ, Bodey GP.
    Pharmacotherapy; 1986 May; 6(4):138-52. PubMed ID: 3534798
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of aztreonam for serious gram-negative bacterial infections.
    Raz R, Flatau E, Sudarsky M, Keness J.
    Chemioterapia; 1988 Feb; 7(1):42-5. PubMed ID: 3378275
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Current state of infectious diseases--potential areas of directed therapy with aztreonam.
    Neu HC.
    Am J Med; 1985 Feb 08; 78(2A):77-80. PubMed ID: 4038580
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.